indium trichloride: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 159675 |
| MeSH ID | M0074839 |
| PubMed CID | 24812 |
| MeSH ID | M0074839 |
| Synonym |
|---|
| indium trichloride |
| I0778 |
| einecs 236-693-3 |
| 12672-70-7 |
| einecs 235-764-6 |
| FT-0627203 |
| AKOS015904611 |
| indium trichloride [mi] |
| 1078729-90-4 |
| indiumtrichloride |
| indium(iii)chloride |
| PSCMQHVBLHHWTO-UHFFFAOYSA-K |
| cl3in |
| indium(3+);trichloride |
| hsdb 6973 |
| indium chloride (incl3) |
| einecs 233-043-0 |
| incl3 |
| NCGC00090704-01 |
| indium(iii) chloride, anhydrous, powder, >=99.999% trace metals basis |
| indiclor (tn) |
| D02107 |
| 10025-82-8 |
| indium (111in) chloride injection (jp17) |
| indium in 111 chloride (usp) |
| indium(iii) chloride, 99.999% trace metals basis |
| indium(iii) chloride, 98% |
| trichloroindigane |
| NCGC00090704-03 |
| NCGC00090704-02 |
| NCGC00090704-04 |
| 36403-62-0 |
| indium (133-in) chloride |
| indium chloride (133incl3) |
| unii-31jb8mkf8z |
| dtxsid8033566 , |
| tox21_400067 |
| cas-10025-82-8 |
| dtxcid6013566 |
| tox21_110999 |
| AKOS015950616 |
| (111)indium chloride |
| indium(iii) chloride, ultra dry |
| mfcd00011058 |
| indium(iii) chloride, anhydrous |
| D91199 |
| Q415500 |
| indium trichloride,99.99% |
| CS-0015717 |
| indium trichloride, trichloroindigane |
| Excerpt | Reference | Relevance |
|---|---|---|
| " A limited disposition study showed that fetuses contained low micromolar concentrations of indium, more indium than maternal liver, and comparable to levels that were toxic in vitro." | ( The reproductive and developmental toxicity of indium in the Swiss mouse. Chapin, RE; Collins, BJ; Davis, BJ; Harris, MW; Hunter, ES; Lockhart, AC, 1995) | 0.29 |
| "(111)In-BLMC (low) was the most toxic to the SCC cell lines." | ( Labelling of bleomycin with Auger-emitter increases cytotoxicity in squamous-cell cancer cell lines. Grénman, R; Jääskelä-Saari, HA; Kairemo, KJ; Ramsay, HA, 1998) | 0.3 |
| " The embryotoxic concentrations were comparable to the serum concentration at a developmentally toxic dose by intravenous administration in an in vivo experiment." | ( Developmental toxicity of indium in cultured rat embryos. Kobayashi, Y; Nakajima, M; Ohno, Y; Sasaki, M; Usami, M, 1999) | 0.3 |
| " In addition, these differences in toxicity were observed despite the two particulate compounds containing similar amounts of indium suggesting that solubilization, not total indium content, better reflects the toxic potential of some ICPs." | ( Macrophage solubilization and cytotoxicity of indium-containing particles as in vitro correlates to pulmonary toxicity in vivo. Bousquet, RW; Gwinn, WM; Morgan, DL; Price, H; Qu, W; Shines, CJ; Taylor, GJ; Waalkes, MP, 2015) | 0.42 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Indium concentrations in the serum of pregnant rats showed low bioavailability of indium by oral administration." | ( Developmental toxicity of indium chloride by intravenous or oral administration in rats. Awano, T; Irie, D; Kobayashi, Y; Nakajima, M; Ohno, Y; Sakemi, K; Sasaki, M; Takahashi, H; Usami, M, 1998) | 0.3 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously shown that rats dosed intratracheally with indium trichloride (InCl3) develop severe lung damage and fibrosis." | ( Pulmonary response of Fischer 344 rats to acute nose-only inhalation of indium trichloride. Blazka, ME; Dixon, D; Luster, MI; O'Connor, RW; Tepper, JS; Winsett, DW, 1994) | 0.29 |
| "Gastroretentive dosage forms have potential for use as controlled-release drug delivery systems." | ( Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. Collett, JH; Fell, JT; Sharma, HL; Smith, A; Whitehead, L, 1998) | 0.3 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.5012 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.2673 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID624030 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 39.8107 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 44.6684 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 2.5119 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| GALC protein | Homo sapiens (human) | Potency | 1.5849 | 28.1838 | 28.1838 | 28.1838 | AID1159614 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.3872 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.6383 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 8.1495 | 0.0002 | 21.2231 | 8,912.5098 | AID1259381; AID743035; AID743036; AID743042; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 40.3934 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| progesterone receptor | Homo sapiens (human) | Potency | 27.3060 | 0.0004 | 17.9460 | 75.1148 | AID1346784 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 35.5742 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 4.8857 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 27.3060 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 10.9622 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 37.1796 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 4.8817 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 11.0337 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| 67.9K protein | Vaccinia virus | Potency | 28.1838 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 8.7413 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 13.3845 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 8.5982 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 61.1306 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 27.3060 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0032 | 0.0100 | 39.5371 | 1,122.0200 | AID588545 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 12.5893 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 2.1690 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 0.0398 | 0.0398 | 16.7842 | 39.8107 | AID995 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 22.3872 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 20.5762 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 17.7828 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 31.6228 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 61.1306 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 73 (34.93) | 18.7374 |
| 1990's | 41 (19.62) | 18.2507 |
| 2000's | 37 (17.70) | 29.6817 |
| 2010's | 49 (23.44) | 24.3611 |
| 2020's | 9 (4.31) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (3.47%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (1.49%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 21 (10.40%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 171 (84.65%) | 84.16% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||